James N. Frame

1.4k citations

41 papers · 995 indexed · h-index 17

Impact in

Internal Medicine top 5%
- Venous Thromboembolism Diagnosis and Management
Hematology top 5%

Papers in ⓘ

Internal Medicine 5
- Venous Thromboembolism Diagnosis and Management 5
Hematology 7
- Platelet Disorders and Treatments 4

Co-authors: Robin Zoň (4 shared papers)Daniel C. Ihde (3 shared papers)Barbara Weiffenbach (3 shared papers)Donald T. Moir (3 shared papers)Neil E. Caporaso (3 shared papers)Bruce E. Johnson (3 shared papers)Linda D. Bosserman (2 shared papers)Bruce D. Cheson (1 shared paper)
Journals: Blood (5 papers)Journal of Oncology Practice (4 papers)Journal of Clinical Oncology (3 papers)Mayo Clinic Proceedings (2 papers)Lung Cancer (2 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

James N. Frame

40 papers receiving 959 citations

Peers

Countries citing papers authored by James N. Frame

Since Specialization

Citations

This map shows the geographic impact of James N. Frame's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James N. Frame with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James N. Frame more than expected).

Fields of papers citing papers by James N. Frame

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James N. Frame. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James N. Frame. The network helps show where James N. Frame may publish in the future.

Co-authors

The 25 scholars most cited alongside James N. Frame, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with James N. Frame Line = papers co-authored together James N. Frame links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 41 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline Journal of Clinical Oncology ·Ethan Basch, D.A. Loblaw, Thomas K. Oliver, Michael A. Carducci, Ronald C. Chen, James N. Frame, Kristina Garrels, Sébastien J. Hotte, Michael W. Kattan, Derek Raghavan, Fred Saad, Mary-Ellen Taplin, Cindy Walker‐Dilks, J. Koudy Williams, Eric Winquist, Charles L. Bennett, Ted Wootton, R. Bryan Rumble, Stacie B. Dusetzina, Katherine S. Virgo	2014	165
2	Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. Journal of Clinical Oncology ·Bruce E. Johnson, J D Bridges, M Sobczeck, J. R. Gray, R. Ilona Linnoila, Adi F. Gazdar, Lynn Hankins, S. M. Steinberg, Margaret Edison, James N. Frame, Harvey I. Pass, J. C. Nesbitt, D. Holden, James L. Mulshine, Eli Glatstein, Daniel C. Ihde	1996	97
3	Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype Human Molecular Genetics ·Richa Saxena, G. L. Shaw, Mary V. Relling, James N. Frame, Donald T. Moir, William E. Evans, Neil E. Caporaso, Barbara Weiffenbach	1994	81
4	American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology Journal of Oncology Practice ·Robin Zoň, James N. Frame, Michael N. Neuss, Ray D. Page, Dana S. Wollins, Steven K. Stranne, Linda D. Bosserman	2016	61
5	Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. Journal of Clinical Oncology ·Bruce D. Cheson, James N. Frame, D. Vena, N Quashu, John M. Sorensen	1998	60
6	Correction of Severe Heparin-Associated Thrombocytopenia with Intravenous Immunoglobulin Annals of Internal Medicine ·James N. Frame, (unknown), (unknown), (unknown)	1989	58
7	COMPARISON OF CAMPATH-1 PLUS COMPLEMENT, ANTI-T CELL RICIN A CHAIN IMMUNOTOXIN, AND SOYBEAN AGGLUTININ ALONE OR IN COMBINATION WITH SHEEP ERYTHROCYTES OR IMMUNOMAGNETIC BEADS Transplantation ·James N. Frame, Nancy Collins, T. Morato Cartagena, Herman Waldmann, Richard J. O’Reilly, B O DUPONT, Nancy A. Kernan	1989	42
8	Clinical significance of the FV:Q506 mutation in unselected oncology patients The American Journal of Medicine ·Gregory A. Otterson, Brian P. Monahan, Nancy Harold, Seth M. Steinberg, James N. Frame, Frederic J. Kaye	1996	38
9	Outcome of Patients With Small-Cell Lung Cancer During 20 Years of Clinical Research at the US National Cancer Institute Mayo Clinic Proceedings ·John P. Chute, David Venzon, Lynn Hankins, Paul Okunieff, James N. Frame, Daniel C. Ihde, Bruce E. Johnson	1997	34
10	Genetic polymorphism of CYP2D6 and lung cancer risk Lung Cancer ·Gail L. Shaw, Roni Falk, James N. Frame, Barbara Weiffenbach, Jonathan C. Nesbitt, Harvey I. Pass, Neil E. Caporaso, Donald T. Moir, Margaret A. Tucker	1994	32
11	Gastrointestinal Visceral Motor Complications of Dermatomal Herpes Zoster: Report of Two Cases and Review Clinical Infectious Diseases ·David R. Tribble, P Church, James N. Frame	1993	31
12	American Society of Clinical Oncology Criteria for High-Quality Clinical Pathways in Oncology Journal of Oncology Practice ·Robin Zoň, Stephen B. Edge, Ray D. Page, James N. Frame, Gary H. Lyman, James Omel, Dana S. Wollins, Sybil R. Green, Linda D. Bosserman	2017	29
13	Online Marketing Strategies of Plastic Surgeons and Clinics: A Comparative Study of the United Kingdom and the United States Aesthetic Surgery Journal ·Reza Nassab, Harshad Navsaria, Stephen P Myers, James N. Frame	2011	28
14	Outcome of Patients With Small-Cell Lung Cancer During 20 Years of Clinical Research at the US National Cancer Institute Mayo Clinic Proceedings ·John P. Chute, David Venzon, Lynn Hankins, Paul Okunieff, James N. Frame, Daniel C. Ihde, Bruce E. Johnson	1997	24
15	A Randomized, Open-Label Pilot Study Comparing Desirudin and Argatroban in Patients With Suspected Heparin-Induced Thrombocytopenia With or Without Thrombosis: PREVENT-HIT Study American Journal of Therapeutics ·Steven W. Boyce, Dennis F. Bandyk, John R. Bartholomew, James N. Frame, Lawrence Rice	2010	24
16	A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients Annals of Oncology ·Joyce O’Shaughnessy, Andrea Denicoff, David Venzon, David N. Danforth, Lori J. Pierce, James N. Frame, Anne Bastian, Bimal C. Ghosh, Barry R. Goldspiel, L.L. Miller, F. Andrew Dorr, Patricia Keegan, N. Ben-Bamch, H. Mrose, Marianne Noone, Kenneth H. Cowan	1994	24
17	Waldenström macroglobulinemia with an IgM-kappa antiepidermal basement membrane zone antibody. PubMed ·Mark W. Cobb, Nouha Domloge‐Hultsch, James N. Frame, K B Yancey	1992	23
18	Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab Journal of Neuro-Oncology ·John A. Vargo, Brian Snelling, Erica Ghareeb, K. John, James N. Frame, John H. Schmidt, Katherine B. Peters	2011	15
19	Debrisoquine metabolism and lung cancer risk. PubMed ·Gail L. Shaw, Roni T. Falk, J Deslauriers, James N. Frame, Jonathan C. Nesbitt, Harvey I. Pass, Haleem J. Issaq, Robert N. Hoover, Margaret A. Tucker	1995	15
20	The Heparin-Induced Thrombocytopenia Task Force Model: Implementing Quality Improvement and Economic Outcome Initiatives Seminars in Hematology ·James N. Frame	2005	14

About James N. Frame

James N. Frame is a scholar working on Internal Medicine, Hematology, Pharmacology, Genetics and Oncology, having authored 41 papers that have together received 995 indexed citations. Recurring topics across this work include Heparin-Induced Thrombocytopenia and Thrombosis (8 papers), Venous Thromboembolism Diagnosis and Management (5 papers), Economic and Financial Impacts of Cancer (4 papers), Pharmacogenetics and Drug Metabolism (4 papers), Lung Cancer Research Studies (4 papers), Platelet Disorders and Treatments (4 papers), Cancer Treatment and Pharmacology (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). The work is most often cited by research in Internal Medicine (110 citations), Hematology (171 citations), Oncology (329 citations), Pharmacology (82 citations) and Chemical Health and Safety (6 citations). James N. Frame has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Robin Zoň, Daniel C. Ihde, Barbara Weiffenbach, Donald T. Moir, Neil E. Caporaso, Bruce E. Johnson, Linda D. Bosserman, Bruce D. Cheson, Ray D. Page and John M. Sorensen. Their work appears in journals such as Blood, Journal of Oncology Practice, Journal of Clinical Oncology, Mayo Clinic Proceedings and Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact